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Abstract
Background: Relatively few data exist on the burden of end-stage renal disease (ESRD) and use of renal replacement
therapy (RRT)–a life-saving therapy–in developing regions. No study has quantified the proportion of patients who develop
ESRD but are unable to access RRT.
Methods: We performed a comprehensive literature search to estimate use and annual initiation of RRT worldwide, and
present these estimates according to World Bank regions. We also present estimates of survival and of etiology of diseases
in patients undergoing RRT. Using data on prevalence of diabetes and hypertension, we modeled the incidence of ESRD
related to these risk factors in order to quantify the gap between ESRD and use of RRT in developing regions.
Results: We find that 1.9 million patients are undergoing RRT worldwide, with continued use and annual initiation at 316
and 73 per million population respectively. RRT use correlates directly (Pearson’s r=0.94) with regional income.
Hemodialysis remains the dominant form of RRT but there is wide regional variation in its use. With the exception of the
Latin American and Caribbean region, it appears that initiation of RRT in developing regions is restricted to fewer than a
quarter of patients projected to develop ESRD. This results in at least 1.2 million premature deaths each year due to lack of
access to RRT as a result of diabetes and elevated blood pressure and as many as 3.2 million premature deaths due to all
causes of ESRD.
Conclusion: Thus, the majority of patients projected to reach ESRD due to diabetes or hypertension in developing regions
are unable to access RRT; this gap will increase with rising prevalence of these risk factors worldwide.
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Introduction
The burden of end-stage renal disease (ESRD) is increasing
across the world, propelled by the rising prevalence of two major
risk factors: diabetes and hypertension [1]. Over the next two
decades, the prevalence of hypertension and diabetes will rise
disproportionately–by more than 80–100%–in economically
developing countries, whereas the projected increase is between
20–50% for developed countries [2,3]. A concomitant rise in
ESRD incidence is anticipated [4], but data on the prevalence and
incidence of ESRD as well as access to therapy in developing
countries remain sparse.
Currently available ESRD registry data only capture informa-
tion on patients who are able to access renal replacement therapy
(RRT), not all those who develop ESRD. Furthermore, RRT is
not a proxy for ESRD incidence and prevalence for two reasons:
1) a large proportion of patients who develop ESRD in low-
income countries are never offered RRT and 2) a significant
proportion of those receiving RRT are removed from therapy or
die annually. Even counts of patients on RRT are not able to be
rigorously collected due in part to poor documentation and lack of
continuity within a fragmented network of both public and private
providers [5]. Registries are rare. Current overviews of RRT in
developing regions come mostly from industry distributed surveys,
expert opinions, or extrapolations from decades-old data [6–8].
These reports rarely include data on the annual initiation rates of
regional RRT, survival, or a breakdown of the underlying diseases
among patients undergoing RRT.
Most importantly, current reports do not capture the large
proportion of patients who die without ever accessing care. An
assessment of RRT in developing regions would therefore
underestimate the true burden of ESRD. Experts in India estimate
that 10 percent of patients who reach ESRD are able to afford
long-term RRT [5]. In a single-center report from South Africa,
half of the patients with ESRD were unable to initiate
government-sponsored treatment [9]. No study has attempted to
systematically quantify this gap in care and its associated mortality.
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e72860In order to present a comprehensive picture of both treated
ESRD (i.e. RRT) and to estimate the potential gap between actual
incidence of ESRD and access to RRT, we performed a
comprehensive literature search to present available data on the
use and annual initiation of RRT, for all countries developed and
developing, and grouped our estimates according to the seven
World Bank regions. We also report available data on survival on
each modality of RRT and the relative prevalence of three major
diseases–diabetes, hypertension, and glomerulonephritis–among
patients undergoing RRT. Finally, we estimate the gap between
RRT and ESRD in developing countries by modeling the
incidence of ESRD attributable to diabetes and hypertension.
Methods
Renal replacement therapy (RRT) is defined as any of
hemodialysis, peritoneal dialysis, or kidney transplant. Our data
are presented according to the following developing regions (as
collated geographically by the World Bank): 1. Europe and
Central Asia, 2. Latin America and Caribbean, 3. Middle East and
North Africa, 4. East Asia and Pacific, 5. South Asia, and 6. Sub-
Saharan Africa (Figure 1). Countries with Gross National Income
greater than $12 276 per capita in 2010 were classified as ‘‘High
Income’’ by the World Bank and are used as comparators in our
analysis [10].
Global use and Initiation of RRT
We used PUBMED and Google Scholar to search for regional
registries and individual country data on RRT. To estimate
incidence and prevalence of RRT, we employed key terms ‘‘renal
registry (region, country)’’ and ‘‘transplant registry (region,
country).’’ Whenever registries from an individual country or a
regional organization were available, we used them as the
predominant source (Appendix S1) [11–15]. For three of the
seven World Bank regions–High Income, Europe and Central
Asia, and Latin America and Caribbean–registries of RRT are
available [16–20]. For regions or countries without registries, we
used data cited in articles describing the state of RRT in a
particular country. To collect these articles, we performed
PUBMED and Google Scholar searches with the key terms
‘‘epidemiology of ESRD (region, country),’’ ‘‘renal replacement
therapy (region, country),’’ ‘‘hemodialysis (region, country),’’
‘‘peritoneal dialysis in (region, country),’’ and ‘‘renal transplants
(region, country).’’ We included all articles starting from year 2000
up to year 2010. Some countries report data to the U.S. Renal
Data System (USRDS) through an individual questionnaire [17].
If we found no recent data for a particular country through
registries or our literature search, we used the data assembled by
USRDS as the primary source. These countries were: Republic of
Korea, Philippines, Taiwan, and Thailand. To estimate use and
initiation rates at a regional level, we totaled mid-2005 population
for each country and assigned a weight to each country’s
population. For example, China’s population constituted 71% of
the data within the East Asia and Pacific region; regional use of
RRT was then a weighted average incorporating this proportion
(see Appendix S2 for an example calculation). We examined the
association between prevalent RRT and regional income, using
data on gross national product (in purchasing power parity units)
for each region.
Estimates of ESRD in Patients with Diabetes and
Hypertension
We estimated ESRD related to diabetes and hypertension in all
individual developing countries. We first collected data on the
prevalence of diabetes as well as the distribution of systolic blood
pressure with mean and standard deviation, for adults over 20
years-old, using data collected on each of the 199 countries
covered in the Global Burden of Metabolic Risk Factors of
Chronic Diseases Collaborating Group [21,22]. We then used the
Multiple Risk Factor Intervention Trial (MRFIT), which is the
Figure 1. World Bank regions. Six of the seven World Bank regions are organized according to geography. The seventh region, the High Income
region (shown here in white) includes North America, Japan, Taiwan, Australia, New Zealand, and European countries–based on a gross national
income greater than $12 276 per capita in 2010. Figure adapted from World Bank Regions, Disease Control Priorities Project. www.dcp2.org/page/
main/BrowseCountries.html.
doi:10.1371/journal.pone.0072860.g001
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alone based on diabetes and blood pressure level–whereas the
United Kingdom Prospective Diabetes Study (UKPDS) provides
incidence of both elevated serum creatinine and ESRD combined
[23–25]. The relative risk for ESRD among MRFIT participants
with diabetes was 12.7 (95% confidence interval: 10.5 to 15.4) over
a baseline risk of 13.7 per 100 000 patient-years among
participants without diabetes (Appendix S3). The MRFIT reports
that relative risk for ESRD increased by two-fold (95% confidence
interval: 1.8 to 2.1) for each standard deviation increase in systolic
blood pressure over a baseline risk of 5.3 per 100 000 patient-years
among participants with optimal blood pressure. Using estimates
of mean blood pressures and prevalence of diabetes from the
global burden of disease (GBD) project, we estimated incidence of
ESRD due to hypertension and diabetes. We then compared these
rates to the annual rates of RRT initiated in each region to
determine a minimum potential gap in ESRD treatment. We
presumed that all patients comprising the gap between estimated
incident ESRD and annual rates of RRT died prematurely.
For select countries in each of the regions, we were also able to
assess the relative proportion of ESRD incidence attributed to
blood pressure and diabetes in comparison to the other causes
such as glomerulonephritis and interstitial nephritis. This allowed
us to calculate a maximum potential gap in ESRD treatment.
Survival by Modality and Etiology of Diseases in Patients
Undergoing RRT
Sufficient data to create regional estimates for survival on RRT
were not available through our literature search. We therefore
present data for the most populous country in each region. Russia,
Brazil, Egypt, China, India, and Nigeria represent the Europe and
Central Asia, Latin America and Caribbean, Middle East and
North Africa, East Asia and Pacific, South Asia and Sub-saharan
Africa regions, respectively. For the relative proportion of patients
on RRT with underlying diabetes, hypertension or glomerulone-
phritis as a cause of ESRD, we found regional estimates for
Europe and Central Asia. In other developing regions, we present
data from the most populous country within the region.
Results
Global use and Initiation of RRT
Our literature search yielded data from year 2000 or later for at
least 70% of countries from each region (Figure 1), with the
exception of Sub-Saharan Africa where incidence estimates are
based on 30% of countries within the region. Roughly 1.9 million
patients are undergoing RRT worldwide, yielding usage of
316 per million population (pmp) and annual initiation of
73 pmp (Table 1). About a third (648,000) resides in developing
regions, which represent 85% of the world’s population.
There is wide variation within and across regions in the fraction
of the population starting and maintained on RRT. However,
RRT use was directly correlated with per capita gross national
product of each region (Figure 2, Pearson’s r=0.94). In Europe
and Central Asia, Russia has the lowest numbers of patients
getting RRT with use of 115 pmp and initiation rate of 20 pmp
[18]. In Latin America and Caribbean, Puerto Rico has the
highest RRT use at 1181 pmp; Nicaragua the lowest at 22 pmp
[20]. In Middle East and North Africa, Lebanon has highest use of
RRT at 818 pmp; Egypt the highest initiation rate at 200 pmp
[6,26]. In East Asia and Pacific, Malaysia has the highest use of
RRT at 574 pmp, and Myanmar the lowest use at 3 pmp [11,27].
In South Asia, Bangladesh reported the highest use of RRT at
83 pmp; Nepal the lowest at 22 pmp. In the Sub-Saharan region,
the Democratic Republic of Congo and Uganda had the lowest
use of RRT at less than one pmp, whereas South Africa had the
highest at about 99 pmp [28].
Although hemodialysis was the most commonly used modality
of RRT, relative use of peritoneal dialysis and transplant also
varied across regions (Figure 3). In Europe and Central Asia, 75%
of prevalent and incident patients undergo hemodialysis. In Latin
America and the Caribbean, hemodialysis is less frequently used
compared to other regions (at 56% of all RRT). Peritoneal dialysis
is the dominant modality in Mexico, El Salvador, Guatemala,
Dominican Republic and Nicaragua. The Middle East and North
Africa region uses hemodialysis primarily, but transplants compose
nearly half of prevalent RRT in Saudi Arabia and Iran. In Sub-
Saharan Africa, peritoneal dialysis is rarely used [28]. Kidney
transplantation is only available in Cameroon, Mauritius, Kenya,
Nigeria, South Africa and Sudan [29].
Estimates of ESRD in Patients with Diabetes and
Hypertension
Tables 2 presents the projected ESRD incidence in patients
with diabetes and hypertension, compared with the initiation of
RRT for 147 countries aggregated by developing country region
(individual country estimates are located in Appendix S3). Overall,
we estimate that 1.2 million patients with diabetes or hypertension
residing in developing countries are unable to access RRT
annually. If we use current data on etiology of ESRD among
patients undergoing RRT (i.e., that between 25–45% of patients
on RRT have diabetes or hypertension in developing regions,
Figure 4) and assume that this ratio reflects ESRD in the general
population, we can estimate the number of patients attributable to
all causes who are not able to access therapy to be closer to 3.2
million annually.
The East Asia and Pacific region had the greatest expected
incidence of ESRD related to diabetes and hypertension–at
311 pmp. The greatest gap between expected incidence of ESRD
and actual initiation of RRT was also seen in this region, with
450,091 patients with diabetes or hypertension unable to access
RRT annually, based on current data of RRT use. Fewer than five
percent of patients projected to develop ESRD related to diabetes
and hypertension access therapy in East Asia and Pacific (2.3%),
South Asia (1.8%), and Sub-saharan Africa (1.5%). In Eastern
Europe and Central Asia 15.7%, in Middle East and North Africa
Table 1. Use and annual initiation of renal replacement
therapy.
World Bank Region Use of RRT Initiation of RRT
(pmp) (pmp)
Eastern Europe and Central Asia 332 79
Latin America and Caribbean 441 147
Middle East and North Africa 325 111
East Asia and Pacific 54 29
South Asia 33 10
Sub-Saharan Africa 20 10
High Income 1283 226
All Regions Combined 316 73
Data are presented according to World Bank Regions, with High Income
countries as comparators.
Abbreviations: RRT–renal replacement therapy, pmp–per million population.
doi:10.1371/journal.pone.0072860.t001
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with diabetes and hypertension access therapy.
Survival by Modality and Etiology of Diseases in Patients
Undergoing RRT
Table 3 presents survival estimates for the most populous
country in each region. With the exception of sub-Saharan Africa
and South Asia, the most populous countries in each developing
region reported first-year dialysis survival over 85% (compared
with 79% in U.S.). Transplant survival was also reported as over
90% in developing regions (compared with 92% in the U.S.).
Diabetes was the most common incident etiology requiring RRT
in Europe and Central Asia at 29% of patients undergoing RRT
(Figure 4). Hypertension was reported as the most common cause
in Brazil (Latin America and Caribbean) and in Egypt (Middle
East and North Africa), at 26% and 33% respectively. Glomer-
ulonephritis was reported as the cause of ESRD in a third or more
of patients undergoing RRT in East Asia and Pacific, Sub-
Saharan Africa and South Asia.
Discussion
Using a comprehensive literature search with emphasis on
regional and individual country registries, we summarize the
initiation and maintenance of RRT according to the seven World
Bank regions, and estimate survival and the underlying etiology of
ESRD among patients undergoing RRT. We also modeled the
gap between anticipated ESRD incidence due to diabetes and
hypertension, and the actual initiation of RRT in patients with
diabetes and hypertension. The latter analysis demonstrates that in
a majority of developing regions fewer than five percent of patients
projected to develop ESRD related to diabetes and hypertension
ever access RRT. Based on the population of adults living in
developing regions, this translates into roughly 1.2 million patients
with diabetes or hypertension dying prematurely due to lack of
access to therapy and over 3 million premature deaths due to all
causes of ESRD and lack of RRT.
We estimate a worldwide use of RRT of 316 pmp and annual
initiation of 73 pmp. This translates into 1.9 million patients
undergoing RRT in 2005, with 441 000 patients initiating RRT
each year–on par with the expected growth in RRT from prior
estimates. Using global data from 1990 and applying a growth rate
of seven percent per year, Lysaught estimated that 1.1 million
people were undergoing dialysis in 2001 [7]. More recently,
through a questionnaire distributed to experts in 122 countries,
Grassman et al. estimated that 1.8 million people were undergoing
dialysis or living with kidney transplants at the end of 2004, with a
growth rate of about six to seven percent per year [8].
We confirm also that a majority of countries rely primarily on
hemodialysis, although there is some variability among and within
regions. Our estimates for prevalent modality use–67% hemodi-
alysis, 7% peritoneal dialysis and 25% transplant–are similar to
those reported previously [8]. We extend current literature by
tabulating these measures for initiation of RRT: 76% for
hemodialysis and 12% each for peritoneal dialysis or transplant.
As expected relative use of both hemodialysis and peritoneal
dialysis drops after the first year as some patients transfer to the
transplant population. However this drop is greater among
patients on peritoneal dialysis, suggesting that a sizable proportion
on peritoneal dialysis either receive kidney transplants or switch to
hemodialysis after one year.
Unlike earlier reports, we also quantify the gap between
incidence of treated ESRD and the anticipated incidence of all
(treated and untreated) ESRD related to diabetes and hyperten-
sion in developing regions. Our model accurately projected ESRD
incidence in patients with hypertension, and underestimated
Figure 2. Regional income and use of RRT. Correlation between income and use of RRT in World Bank Regions (Pearson’s r=0.94). Income is
reported as GNP in U.S. dollars per capita PPP from 2005. Abbreviations: RRT-renal replacement therapy, GNP-gross national income, PPP-purchasing
power parity, ECA-Eastern Europe and Central Asia, LAC-Latin America and Caribbean, MNA-Middle East and North Africa, EAP-East Asia and Pacific,
SA-South Asia and SSA-Sub-Saharan Africa.
doi:10.1371/journal.pone.0072860.g002
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PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e72860Figure 3. Annual initiation of RRT and use of RRT by modality. Hemodialysis is the most commonly used therapy within developing regions.
Transplants are relatively more commonly used and initiated therapies in MNA and SA regions. Peritoneal dialysis is relatively more commonly used
and initiated in LAC. Abbreviations: RRT-Renal replacement therapy, HD-Hemodialysis, PD-Peritoneal dialysis, ECA-Eastern Europe and Central Asia,
LAC-Latin America and Caribbean, MNA-Middle East and North Africa, EAP-East Asia and Pacific, SA-South Asia and SSA-Sub-saharan Africa.
doi:10.1371/journal.pone.0072860.g003
Table 2. Estimated incident ESRD and reported initiation of RRT in patients with diabetes and hypertension.
World Bank Region
Estimated incident
ESRD in patients with
diabetes
Estimated incident
ESRD in patients with
hypertension
Total estimated ESRD
in patients with
diabetes or
hypertension
Estimated gap in access
to therapy in patients
with diabetes or
hypertension
(pmp) (pmp) (pmp)
Eastern Europe and Central Asia 88 138 226 90,935
Latin America and Caribbean 91 118 209 77,794
Middle East and North Africa 82 114 196 49,729
East Asia and Pacific 146 165 311 450,091
South Asia 102 105 207 302,147
Sub-Saharan Africa 99 140 239 176,508
Incident ESRD is modeled using relative risk of ESRD in patients with diabetes and hypertension, as reported in the Multiple Risk Factor Intervention Trial [23,24]. Sources
for reported incident RRT in patients with diabetes and hypertension are noted in Appendix S3.
Abbreviations: ESRD–end-stage renal disease, RRT–renal replacement therapy.
doi:10.1371/journal.pone.0072860.t002
End-Stage Renal Disease in Developing Regions
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counts available from USRDS. Using this model, we find that in a
majority of developing regions, initiation rates of RRT fall below
twenty-five percent of the projected incident ESRD related to
diabetes or hypertension. Initiation rates of RRT track more
closely with the income rather than with the prevalence of risk
factors for ESRD. For example, the prevalence of diabetes among
adults in India and Egypt is close to that of the U.S. but initiation
of RRT among these patients falls well below the U.S. Similarly,
the prevalence of hypertension in Nigeria (Sub-Saharan Africa) is
higher than reported in India and China, but RRT initiation is
much lower.
One exception to the association between gross national
product and use of RRT was Eastern Europe and Central Asia.
Despite similar per capita income, and projections of hypertension
and diabetes-related ESRD, the Eastern European and Central
Asian countries had lower initiation rates of RRT compared with
Latin America and Caribbean countries. We speculate that
differences in RRT rates may reflect the Brazilian government’s
policy of fully reimbursing RRT even for patients using privatized
facilities as well as the greater use of peritoneal dialysis in many
Latin American countries.
In many regions, RRT-associated survival was actually higher
than among countries classified as ‘‘High Income.’’ For trans-
plants, one explanation lies in the expected graft survival: in the
High Income region deceased donor transplants predominate,
whereas in the developing regions living donor transplants
predominate [30]. Patients with significant comorbidities are less
likely to be accepted into RRT programs in developing regions. In
South Africa where government-sponsored RRT is offered to
patients who fulfill criteria for eventual transplantation, patients
over 60 years of age and patients with diabetes were significantly
less likely to be on RRT [9]. Thus, higher survival rates may
reflect the better underlying health status of patients selected for
RRT in developing regions. Glomerulonephritis was the most
common etiology of ESRD among patients undergoing RRT in
East Asia, South Asia and Sub-Saharan Africa. Again, whether
this reflects a true difference in underlying etiology of ESRD in
these regions, or the disproportionate selection of patients with
glomerulonephritis (who tend to be considerably younger in age
Figure 4. Proportion of diabetes, hypertension and glomerulonephritis among patients undergoing RRT. Data for ECA are from registry
data representing 60% of its population; for all other developing regions, data are from the most populous country within the region. Abbreviations:
HD-Hemodialysis, PD-Peritoneal dialysis, ECA-Eastern Europe and Central Asia, LAC-Latin America and Caribbean, MNA-Middle East and North Africa,
EAP-East Asia and Pacific, SA-South Asia and SSA-Sub-Saharan Africa.
doi:10.1371/journal.pone.0072860.g004
Table 3. Estimates of first-year survival on renal replacement therapy.
World Bank Region Representative country One-year survival on dialysis (%)
One-year survival with
transplant (%)
[Range of estimate*] [Range of estimate*]
Eastern Europe and Central Asia Russia 88 [80–94] 90 [90–98]
Latin America and Caribbean Brazil 87 [75–87] 95 [91–98]
Middle East and North Africa Egypt 97 [88–97] 95 [83–98]
East Asia and Pacific China 89 [87–96] 98 [95–98]
South Asia India 77 [65–90] 90 [85–94]
Sub-Saharan Africa Nigeria 63 [63–90] 95 [78–95]
Survival is reported as survival on the therapy, for the most populous country in the World Bank Region.
*Ranges represent data from other countries within the region. Dialysis estimates are for hemodialysis and peritoneal dialysis.
doi:10.1371/journal.pone.0072860.t003
End-Stage Renal Disease in Developing Regions
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hypertension/vascular disease) is unclear.
A higher proportion of patients on RRT were using peritoneal
dialysis in the Latin America and Caribbean region than in other
regions (23% compared with 6% in High Income region).
Preference for peritoneal dialysis in Latin America–Mexico in
particular–may reflect a purposeful strategy to deal with the
shortage of nephrologists and dialysis centers. Historically, leading
Mexican clinicians trained in peritoneal dialysis and disseminated
the technique early [31].Rates of peritonitis and survival observed
in Mexico are similar to that of the U.S. and other High Income
countries [32]. A similar approach could be adopted in other
developing countries to help increase access to RRT [33].
Two developing regions–Latin America and Caribbean, and
Middle East and North Africa–provide RRT for comparatively
greater proportion of patients. However, resources allocated to
RRT in these regions are not likely to be sustainable, and may be
unrealistic targets for other regions. The Brazilian Ministry of
Health spent U.S. $500 million on RRT in 2004 [34]; in Egypt
fully 28% ($100 million) of the health care budget was spent on
government-sponsored RRT in 2008 [35]. The cost of peritoneal
dialysis in developing regions is not necessarily lower than that of
hemodialysis, largely due to the expense of importing solutions and
lack of governmental policies that support high-volume peritoneal
dialysis centers (with the exception of Mexico) [33]. Transplan-
tation activity remains predominantly reliant on live organ
donation. Thus, with the projected growth in ESRD, these regions
are also likely to face additional challenges in financing care for
larger groups of prospective patients.
Our study has several strengths. We provide updated estimates
of RRT use for new and existing patients. In addition we provide
estimates for survival and relative prevalence of three major
etiologies for ESRD among patients undergoing RRT. Organiza-
tion of our data according to World Bank regions allows a
comparison between the prevalence of risk factors, regional
income and use of RRT. Most importantly, we used a novel
approach–modeling projected rates of incident ESRD based on
available estimates of diabetes and hypertension prevalence–to
provide a better approximation of the underlying rates of ESRD in
each region. This allows us to explore the gap between probable
‘‘true’’ ESRD incidence and treated ESRD incidence recorded in
registries and other sources.
An important limitation of this approach is that it assumes the
progression to ESRD among patients with diabetes and hyper-
tension will be similar to that seen in the U.S. Progression rates
vary among different populations, with African Americans at
higher risk for ESRD due to hypertension, for example [36].
Similarly Hallan et al. have demonstrated that although preva-
lence of CKD in Norway approaches that of the U.S., Norwegians
are less likely to progress to ESRD, arguably due to a lower
prevalence of obesity and earlier referral to nephrologists [37].
Thus, more population-specific models regarding rates of
progression and competing risks for mortality are required to
refine future projections. In addition our estimates are limited to
patients with diabetes or hypertension. Our model does capture the
two risk factors most likely to drive global ESRD incidence over
the next two decades. The rapidly rising prevalence of diabetes
and hypertension has been documented worldwide, and with
improving survival from communicable diseases, many more
patients will survive to develop ESRD. The gaps in care we have
identified between actual and treated ESRD in most developing
regions will only grow larger unless comprehensive approaches to
CKD surveillance and management are adopted. Such policies
will require careful deliberation and prioritization among politi-
cians, health policy-makers, and individuals within each country or
region.
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